Shots:
The US FDA has granted FTD to LTI-03 for the treatment of idiopathic pulmonary fibrosis
The P-II (RENEW) trial is a randomized, PBO-controlled study (n=~120) evaluating the safety, tolerability, and efficacy of LTI-03 for idiopathic pulmonary fibrosis across the US, UK, Australia, Poland, and Germany. Patients will receive 1 of 2 LTI-03 doses or…
